Forget Biotech's Binary Bets: This Dividend Stock Collects Royalties on Blockbusters InsteadFool - Investing News · 22 hr ago
3 Reasons Royalty Pharma Is a Dividend Stock You Never Have to SellThe Motley Fool · 3 days ago
BioAge Labs (NASDAQ:BIOA) and Royalty Pharma (NASDAQ:RPRX) Critical ComparisonDefense World · 4 days ago
Royalty Pharma declares fourth quarter 2026 dividendGlobeNewsWire · Oct 16, 2026
Royalty Pharma to announce third quarter 2026 financial results on November 4, 2026GlobeNewsWire · Oct 9, 2026
Why Royalty Pharma (RPRX) is Poised to Beat Earnings Estimates AgainZacks Investment Research · Oct 8, 2026Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 5, 2026 | $1.27 | $1.32 | Beat |
| May 6, 2026 | $1.21 | $1.30 | Beat |
| Feb 11, 2026 | $1.29 | $1.46 | Beat |
| Nov 5, 2025 | $0.99 | $1.17 | Beat |
| Aug 6, 2025 | $1.03 | $1.14 | Beat |
| May 8, 2025 | $0.95 | $1.06 | Beat |